Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy

Eric Guedj^{1,2,3}, Thomas Graillon^{4,5}, Olivier Chinot⁶, and David Taieb^{1,3,7}

¹ Service de Médecine Nucléaire, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

² Aix-Marseille Université, CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, Marseille, France

³ CERIMED, Aix-Marseille Université, Marseille, France

⁴ Service de Neurochirurgie, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

⁵ Aix Marseille Université, CNRS, UMR7286, CRN2M, Marseille, France.

⁶ Service de Neuro-Oncologie, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

⁷ Aix Marseille Université, Inserm, U1068-CNRS 7258, Cancer Research Center of Marseille, Marseille, France

Running title: PRRT perspectives for meningiomas

Word count: 658

Address for correspondence:

Eric Guedj, MD, PhD

eric.guedj@ap-hm.fr

Service Central de Biophysique et Médecine Nucléaire, Hôpital de la Timone, 264 rue Saint Pierre, 13005 Marseille, France.

Tel.: +33-491385558; Fax: +33-491384769

With a worldwide incidence of 45,000 cases, meningioma is the most common nonglial primary intracranial tumour. Although often associated with indolent behaviour, many patients present tumours with aggressive features and poor outcomes. After complete resection, the 5-year recurrence rate is estimated to 5%, 40% and 80% in grades I (benign), II (atypical) and III (anaplastic), respectively [1,2]. Very few treatment options are available at this step. The progression-free survival of aggressive recurrent meningiomas decreases below 30% at 6 months, while the median overall survival is of 3 years for patients with grade III [3]. It is therefore of main importance to develop new treatment options.

In recent years, Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSAs) has gained an increasing role in patients with somatostatin receptor (SST)-expressing tumours, identified and selected in a theranostic view by the use of a companion diagnostic agent corresponding to the same SSA labelled with Indium-111 or preferably Gallium-68 for molecular imaging. In this line, the PRRT results obtained from the NETTER-1 trial in patients with advanced midgut neuroendocrine tumours (NETs) have given a new impetus towards the use of therapeutic nuclear medicine in oncology [4]. Although NETs are the prime example of positive SST tumours, meningiomas express comparable amounts of SST and, unlike NET, also express this profile in aggressive forms [5]. This could potentially open the therapeutic window for PRRT in meningiomas. From a biological standpoint, a recent study confirmed that meningiomas overexpress SST2, with a high expression pattern in 67% of cases, comparable to gastroenteropancreatic NET [5]. These findings agree with imaging studies with ^{68}Ga -DOTA-SSAs that showed highly elevated tumour uptake [6,7]. ^{68}Ga -DOTA-SSAs PET/CT is currently recommended in meningioma patients by the international recommendation of the RANO group for differential diagnosis, grading, delineation, radiation planning, follow-up, evaluation of response and progression [1]. To

date, the application of PRRT for meningiomas has been mainly used on a compassionate basis. Approximately 120 meningioma patients treated with PRRT have been reported [8-15]. These studies are limited by mixing various types of meningiomas, different PRRT schedules and follow-up imaging studies. In addition, the growth rate before treatment was not always documented, limiting the interpretation of the PFS, particularly in grade I and “low” grade II meningioma patients. Although half of these patients were treated by external radiotherapy prior to PRRT, safety and clinical tolerance were excellent. Moreover, a study has even shown that concomitant treatment by PRRT and external radiotherapy was also well tolerated [14]. Regarding oncologic endpoints, these promising studies have described disease stabilization for grades I and less aggressive grades II meningioma in most cases, with a 6-month PFS ranging from 57 to 100%. By contrast, no clear benefit has been reported for more aggressive grade II and III meningiomas thus far. Beyond the expression of the molecular target, the overview of these studies underlines the need for the PRRT schedule to be tailored to each situation with the integration of several factors in the decision-making process, such as the extent of disease, growth rate, grade, molecular genetics and SST expression. Regarding dosimetry, the relationships between the absorbed dose and the response rate are not well established. To increase the absorbed dose while preserving at risk organs, two main options have been proposed [16]: the standard 7.4 GBq/cycle with a variation in the number of cycles until the Biological Effective Dose limits of kidney and bone marrow are reached [17, 18] or 4 fixed cycles with variable activity per cycle to reach the dose limits [19].

A prospective evaluation of PRRT in meningioma patients with an integration of a dosimetry-based approach, especially in at-risk organs, would be an important step towards a new spin on treating meningioma patients. Improvement roadmaps include the use of various therapeutic isotopes depending on situations, radiosensitizers, intelligence computations, and

potential meningioma-directed applications. Further development also may include the evaluation of early postoperative PPRT in grade II meningiomas as an alternative or in combination with classical radiotherapy.

Compliance with Ethical Standards:

Funding: This work has been conducted in the framework of DHU-Imaging thanks to the support of the A*MIDEX project (n°ANR-11-IDEX-0001-02) (« Investissements d’Avenir » French Government programme, managed by the French National Research Agency (ANR)).

Conflict of Interest: None

Ethical approval: This article does not contain any studies with human participants performed by any of the authors

References

1. Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma-report of the RANO/PET Group. *Neuro Oncol.* 2017;19:1576-87. doi:10.1093/neuonc/nox112.
2. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. *Lancet Oncol.* 2016;17:e383-91. doi:10.1016/S1470-2045(16)30321-7.
3. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. *Neuro Oncol.* 2014;16:829-40. doi:10.1093/neuonc/not330.
4. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of. *N Engl J Med.* 2017;376:125-35. doi:10.1056/NEJMoa1607427.
5. Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. *J Neurosurg.* 2017;127:660-9. doi:10.3171/2016.8.JNS16995.
6. Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo M, et al. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. *PLoS One.* 2014;9:e111624. doi:10.1371/journal.pone.0111624.
7. Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? *Neuro Oncol.* 2016;18:1021-7. doi:10.1093/neuonc/now001.
8. Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas. *J Nucl Med.* 2015;56:1748-51. doi:10.2967/jnumed.115.155853.
9. Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. *J Nucl Med.* 2015;56:171-6. doi:10.2967/jnumed.114.147256.
10. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. *Eur J Nucl Med Mol Imaging.* 2009;36:1407-16. doi:10.1007/s00259-009-1115-z.
11. Sabet A, Ahmadzadehfard H, Herrlinger U, Wilinek W, Biersack HJ, Ezziddin S. Successful radiopeptide targeting of metastatic anaplastic meningioma: case report. *Radiat Oncol.* 2011;6:94. doi:10.1186/1748-717X-6-94.
12. Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. *Neuro Oncol.* 2016;18:1538-47. doi:10.1093/neuonc/now060.
13. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. *J Nucl Med.* 2006;47:1599-606.
14. Kreissl MC, Hänscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. *Radiat Oncol.* 2012;7:99. doi:10.1186/1748-717X-7-99.
15. Backhaus P, Huss S, Kösek V, Weckesser M, Rahbar K. Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy. *Clin Nucl Med.* 2018;43:e184-e5. doi:10.1097/RLU.0000000000002077.
16. Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to. *Eur J Nucl Med Mol Imaging.* 2018. doi:10.1007/s00259-018-4044-x.

17. Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing ¹⁷⁷Lu-DOTA-octreotate treatment. *J Nucl Med*. 2013;54:33-41. doi:10.2967/jnumed.112.107524.
18. Sundlöv A, Sjögren-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised. *Eur J Nucl Med Mol Imaging*. 2017;44:1480-9. doi:10.1007/s00259-017-3678-4.
19. Del Prete M, Buteau FA, Beauregard JM. Personalized. *Eur J Nucl Med Mol Imaging*. 2017;44:1490-500. doi:10.1007/s00259-017-3688-2.